ClinicalTrials.gg
Not yet recruitingNCT07876674Updated Oct 15, 2026

A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia

A Phase 3 interventional study of SR604 in Hemophilia A, Hemophilia A and B and Hemophilia B, sponsored by Shanghai RAAS Blood Products Co., Ltd.. Not yet recruiting. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Shanghai RAAS Blood Products Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Study summary

This is a single-arm, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of prophylactic treatment with SR604 Injection in hemophilia A/B patients with or without inhibitors.

02

Conditions studied

  • Hemophilia A
  • Hemophilia A and B
  • Hemophilia B
03

In context

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

This study's planned enrollment of 90 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.

Browse Hemophilia A studies →

Lead sponsor

Shanghai RAAS Blood Products Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

      1. Patients aged ≥12 years and ≤65 years at the time of signing the form (ICF), male or female;

        • 2. Patients with hemophilia A with FVIII activity level \<1% or hemophilia B with FIX activity level ≤2%, confirmed by testing during the screening period or by prior test results;
        • - For patients without inhibitors: FVIII or FIX inhibitor test results during the screening period are negative or below the lower limit of normal (LLN); no bleeding treated with bypassing agents due to inhibitors within at least 6 months prior to screening; no history of immune tolerance induction (ITI) within 3 years prior to screening; and ≥150 exposure days (EDs) of clotting factor replacement therapy;
        • - For patients with inhibitors: FVIII or FIX inhibitor titer during the screening period is high titer (≥5 Bethesda units/mL [BU/mL]), or the inhibitor titer is low titer (0.6 BU/mL or the ≤ inhibitor titer \<5 BU/mL) and treatment with a bypassing agent (rFVIIa or PCC) has already been initiated;
        • 3. ≥6 bleeds requiring treatment with a clotting factor replacement or bypassing agent within the 6-month run-in period (bleeds related to surgery are not counted);
        • 4. No active bleeding symptoms prior to the first administration of SR604 Injection;
        • 5. Able to understand the procedures and methods of this clinical trial, with adequate informed consent; the patient voluntarily participates and signs the informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with a known history of to the product or any of its components; 2. Intolerance to subcutaneous (SC) injection, or presence of other local skin abnormalities or skin diseases that affect dosing and safety assessment; 3. Meeting any of the following criteria during the screening period or prior to enrollment:

    1. \<60 g/L;
    2. count \<100×10⁹/L;
    3. Abnormal hepatic or renal function: (ALT) or aspartate aminotransferase (AST) ≥2.5× the (ULN), or total ≥1.5× ULN; or serum creatinine (Cr) ≥1.5× ULN;
    4. Positive for anti- (HIV) antibodies; 4. Markedly abnormal coagulation parameters caused by diseases other than hemophilia A or B (e.g., platelet disorders, vitamin K deficiency, etc.); 5. Patients with protein C deficiency or protein S deficiency; 6. History of thrombosis or family history of thrombosis, or history of thrombophilia; 7. Intracranial hemorrhage due to hemophilia A or B within 2 years prior to signing the form (ICF); 8. Suffering from severe cardiac disease, such as unstable angina, congestive heart failure ( [NYHA] class ≥III), severe arrhythmia ( >480 ms, corrected by Fridericia's formula), uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), etc.; 9. Received any product containing FVIII within 72 hours prior to the first administration of the investigational product; received any product containing FIX within 96 hours prior to the first administration of the investigational product; received recombinant human coagulation factor VIIa (rFVIIa) within 48 hours prior to the first administration of the investigational product; the for long-acting forms of the above medicinal products is less than 5 half-lives; 10. Used within 1 week prior to screening, or requiring during the trial, any anticoagulants, antifibrinolytics, or chemical drugs, biological products, or traditional Chinese medicines that affect platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin; 11. Received non-factor regular replacement therapy within 6 months prior to signing the informed consent form (ICF), such as emicizumab, marstacimab, Fitusiran injection (fitusiran sodium), etc.; 12. Underwent major surgery (e.g., orthopedic surgery, abdominal surgery) within 1 month prior to signing the informed consent form (ICF), or planned to undergo surgery during the study period; 13. Enrolled in another clinical trial and received drug/medical device treatment within 1 month prior to signing the informed consent form (ICF); 14. Patients with mental illness or significant psychiatric disorders, or incapacity or cognitive impairment due to other causes; 15. Planning to have children or donate sperm during the entire trial period and within 6 months after the last dose, or unwilling to use effective physical (e.g., condoms, etc.); 16. Other conditions considered by the investigator to make the patient unsuitable for enrollment, such as alcohol abuse, anticipated poor compliance of the trial participant that makes it impossible to complete dosing and trial follow-up, poorly controlled other chronic diseases, or presence of severe systemic diseases.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    SR604

    Participants with Hemophilia A or Hemophilia B will receive SR604 dose 1 as multiple SC injections every 4-weeks

    Drug: SR604

Interventions

  • DrugSR604

    SR604 will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Treated total annualized bleeding rate (ABR) over 28 weeks of treatment

    Time frame: Through week 28

Secondary outcomes

  1. Treated total annualized bleeding rate (ABR) over 52 weeks of treatment.

    Time frame: Through week 52

  2. Treated and untreated spontaneous annualized bleeding rate

    Time frame: Through week 52

  3. Treated and untreated traumatic annualized bleeding rate

    Time frame: Through week 52

  4. Treated and untreated annualized joint bleeding rate (AJBR)

    Time frame: Through week 52

  5. Total annualized bleeding rate, including treated and untreated bleeding events

    Time frame: Through week 52

  6. Untreated total annualized bleeding rate

    Time frame: Through week 52

  7. Treated and untreated target joint annualized bleeding rate

    Time frame: Through week 52

  8. Treated total annualized bleeding rate in patients with and without inhibitors

    Time frame: Through week 52

  9. Proportion of patients with no treated bleeding events

    Time frame: Through week 52

  10. Change in the number of target joints

    Time frame: Through week 52

  11. Change from pre-treatment in Hemophilia Joint Health Score (HJHS)

    Time frame: Through week 52

  12. Change from pre-treatment in health index scale (EQ-5D-5L)

    Time frame: Through week 52

Other outcomes

  1. The incidences of AE/SAE/AESI

    Time frame: Through week 52

  2. Number of participants positive for anti-drug antibody (ADA) and neutralizing antibody (NAb) and their incidence

    Time frame: Through week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 12 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07876674
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Research and Development
Contact
hanyu@raas-corp.com
862122130888

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SR604

Start the discussion